Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
May 23 2023 - 3:05PM
Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH)
today announced that it was selected by Krystal Biotech, Inc.
(“Krystal Biotech”) (Nasdaq: KRYS) as part of a limited
distribution specialty pharmacy network for VYJUVEK™. VYJUVEK was
approved by the U.S. Food & Drug Administration (FDA) on May
19, 2023 for the treatment of patients with dystrophic
epidermolysis bullosa (DEB).
VYJUVEK is a topical gene therapy indicated for the treatment of
wounds in patients 6 months of age and older with dystrophic
epidermolysis bullosa with mutation(s) in the collagen type VII
alpha 1 chain (COL7A1) gene.
Through the national footprint of over 95 specialty pharmacies
strategically located across the U.S., Option Care Health will
serve as the only specialty pharmacy provider for mixing and
delivering prepared VYJUVEK gel administration syringes to
professional healthcare and home settings. Option Care Health will
collaborate with Amedisys, Inc. on this effort, including for
Amedisys nurses to deliver and administer VYJUVEK to patients.
Amedisys is a leading healthcare at home company that has a strong
presence in hospital at home, home health, hospice, palliative, and
high-acuity care services.
“We are honored to work with Krystal Biotech in providing access
to this novel treatment, which is expected to help children and
adults suffering from a rare disease,” said John C. Rademacher,
President and Chief Executive Officer of Option Care Health. “The
ability to administer this non-invasive treatment in the comfort of
one’s home will help ensure that this medicine gets to those who
need it the most. We are honored to partner with Amedisys on this
important endeavor, building on a history of successful
collaboration between our two companies that brings innovative
solutions to provide high-quality care in the home.”
About Dystrophic Epidermolysis Bullosa
(DEB)
DEB is a rare and severe disease that affects the skin and
mucosal tissues. It is caused by one or more mutations in a gene
called COL7A1, which is responsible for the production of the
protein type VII collagen (COL7) that forms anchoring fibrils that
bind the dermis (inner layer of the skin) to the epidermis (outer
layer of the skin). The lack of functional anchoring fibrils in DEB
patients leads to extremely fragile skin that blisters and tears
from minor friction or trauma. DEB patients suffer from open
wounds, which leads to skin infections, fibrosis which can cause
fusion of fingers and toes, and ultimately an increased risk of
developing an aggressive form of squamous cell carcinoma which, in
severe cases, can be fatal.
About Option Care Health
Option Care Health is the nation’s largest independent provider
of home and alternate site infusion services. With over 7,500 team
members including more than 4,500 clinicians, we work
compassionately to elevate standards of care for patients with
acute and chronic conditions in all 50 states. Through our clinical
leadership, expertise and national scale, Option Care Health is
reimagining the infusion care experience for patients, customers
and team members. To learn more, please visit our website at
OptionCareHealth.com.
OPTION CARE HEALTH CONTACTMike ShapiroChief
Financial Officer(312)
940-2538investor.relations@optioncare.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2023 to Jul 2024